Literature DB >> 18988293

Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period.

Pamela M McMahon1, Chung Yin Kong, Milton C Weinstein, Angela C Tramontano, Lauren E Cipriano, Bruce E Johnson, Jane C Weeks, G Scott Gazelle.   

Abstract

BACKGROUND: Simulation modeling can synthesize data from single-arm studies of lung cancer screening and tumor registries to investigate computed tomography (CT) screening. This study estimated changes in lung cancer outcomes through 2005, had chest CT screening been introduced in 1990.
METHODS: Hypothetical individuals with smoking histories representative of 6 US cohorts (white males and females aged 50, 60, and 70 years in 1990) were simulated in the Lung Cancer Policy Model, a comprehensive patient-level simulation model of lung cancer development, screening, and treatment. A no screening scenario corresponded to observed outcomes. We simulated 3 screening scenarios in current or former smokers with > or =20 pack-years as follows: 1-time screen in 1990; and annual, and twice-annually screenings beginning in 1990 and ending in 2005. Main outcomes were days of life between 1990 and 2005 and life expectancy in 1990 (estimated by simulating life histories past 2005).
RESULTS: All screening scenarios yielded reductions (compared with no screening) in lung cancer-specific mortality by 2005, with larger reductions predicted for more frequent screening. Compared with no screening, annual screening of ever-smokers with at least 20 pack-years of cigarette exposure provided ever-smokers with an additional 11 to 33 days of life by 2005, or an additional 3-10 weeks of (undiscounted) life expectancy. In sensitivity analyses, the largest effects on gains from annual screening were due to reductions in screening adherence and increased smoking cessation.
CONCLUSIONS: The adoption of CT screening, had it been available in 1990, might have resulted in a modest gain in life expectancy.

Entities:  

Mesh:

Year:  2008        PMID: 18988293      PMCID: PMC2782879          DOI: 10.1002/cncr.23962

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

Review 1.  Simulation modeling of outcomes and cost effectiveness.

Authors:  S D Ramsey; M McIntosh; R Etzioni; N Urban
Journal:  Hematol Oncol Clin North Am       Date:  2000-08       Impact factor: 3.722

Review 2.  A critique of hypertension treatment trials and of their evaluation.

Authors:  J I Robertson
Journal:  J Eval Clin Pract       Date:  2001-05       Impact factor: 2.431

3.  Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study.

Authors:  Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Karen M Kuntz; Jo-Anne O Shepard; Stephen J Swensen; G Scott Gazelle
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

4.  Overdiagnosis in lung cancer: different perspectives, definitions, implications.

Authors:  Peter B Bach
Journal:  Thorax       Date:  2008-04       Impact factor: 9.139

5.  Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Authors:  D Schrag; K M Kuntz; J E Garber; J C Weeks
Journal:  JAMA       Date:  2000-02-02       Impact factor: 56.272

6.  Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer.

Authors:  John K Gohagan; Pamela M Marcus; Richard M Fagerstrom; Paul F Pinsky; Barnett S Kramer; Philip C Prorok; Susan Ascher; William Bailey; Brenda Brewer; Timothy Church; Deborah Engelhard; Melissa Ford; Mona Fouad; Matthew Freedman; Edward Gelmann; David Gierada; William Hocking; Subbarao Inampudi; Brian Irons; Christine Cole Johnson; Arthur Jones; Gena Kucera; Paul Kvale; Karen Lappe; William Manor; Alisha Moore; Hrudaya Nath; Sarah Neff; Martin Oken; Michael Plunkett; Helen Price; Douglas Reding; Thomas Riley; Martin Schwartz; David Spizarny; Roberta Yoffie; Carl Zylak
Journal:  Lung Cancer       Date:  2005-01       Impact factor: 5.705

7.  Lung cancer incidence in never smokers.

Authors:  Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

8.  Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute.

Authors:  John Gohagan; Pamela Marcus; Richard Fagerstrom; Paul Pinsky; Barnett Kramer; Philip Prorok
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

9.  Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR).

Authors:  Thierry Blanchon; Jeanne-Marie Bréchot; Philippe A Grenier; Gilbert R Ferretti; Etienne Lemarié; Bernard Milleron; Dominique Chagué; François Laurent; Yves Martinet; Catherine Beigelman-Aubry; François Blanchon; Marie-Pierre Revel; Sylvie Friard; Martine Rémy-Jardin; Manuela Vasile; Nicola Santelmo; Alain Lecalier; Patricia Lefébure; Denis Moro-Sibilot; Jean-Luc Breton; Marie-France Carette; Christian Brambilla; François Fournel; Alexia Kieffer; Guy Frija; Antoine Flahault
Journal:  Lung Cancer       Date:  2007-07-12       Impact factor: 5.705

10.  The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening.

Authors:  Juan P Wisnivesky; Alvin I Mushlin; Nachum Sicherman; Claudia Henschke
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

View more
  19 in total

1.  Calibrating models in economic evaluation: a seven-step approach.

Authors:  Tazio Vanni; Jonathan Karnon; Jason Madan; Richard G White; W John Edmunds; Anna M Foss; Rosa Legood
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

Review 2.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

3.  Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis.

Authors:  Kathryn P Lowry; G Scott Gazelle; Michael E Gilmore; Colden Johanson; Vidit Munshi; Sung Eun Choi; Angela C Tramontano; Chung Yin Kong; Pamela M McMahon
Journal:  Cancer       Date:  2015-02-03       Impact factor: 6.860

4.  Calibration of disease simulation model using an engineering approach.

Authors:  Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Value Health       Date:  2009-01-12       Impact factor: 5.725

5.  Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.

Authors:  Angela C Tramontano; Lauren E Cipriano; Chung Yin Kong; Jo-Anne O Shepard; Michael Lanuti; G Scott Gazelle; Pamela M McMahon
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

6.  Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem.

Authors:  Eric J Feuer; David T Levy; William J McCarthy
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

7.  Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.

Authors:  Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Angela C Tramontano; Lauren E Cipriano; Colleen Bouzan; G Scott Gazelle
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

8.  Chapter 13: CISNET lung models: comparison of model assumptions and model structures.

Authors:  Pamela M McMahon; William D Hazelton; Marek Kimmel; Lauren D Clarke
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

9.  Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model.

Authors:  Zhihui Wang; Christina M Birch; Jonathan Sagotsky; Thomas S Deisboeck
Journal:  Bioinformatics       Date:  2009-07-04       Impact factor: 6.937

10.  Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach.

Authors:  Jihyoun Jeon; Theodore R Holford; David T Levy; Eric J Feuer; Pianpian Cao; Jamie Tam; Lauren Clarke; John Clarke; Chung Yin Kong; Rafael Meza
Journal:  Ann Intern Med       Date:  2018-10-09       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.